EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

IPC The Hospitalist Stock Hits New 52-Week High (IPCM)

By TheStreet Wire 04/01/11 - 10:26 AM EDT

Find out if (IPCM) is in Cramer's Portfolio.

NEW YORK (TheStreet) -- IPC The Hospitalist Company (Nasdaq:IPCM) hit a new 52-week high Friday as it traded at $46.70 compared with its previous 52-Week high of $46.50. IPC The Hospitalist is changing hands at $46.61 with 7,119 shares traded as of 10 a.m. ET. Average volume has been 100,800 shares over the past 30 days.

IPC The Hospitalist has a market cap of $729.3 million and is part of the health care sector and health services industry. Shares are up 16.4% year to date as of the close of trading on Thursday.

IPC The Hospitalist Company, Inc., a physician group practice company, provides hospitalist services in the United States. The company has a P/E ratio of 30.6, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 16.4.

Practice your IPCM trading strategies and win cash in our stock game.

TheStreet Ratings rates IPC The Hospitalist as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full IPC The Hospitalist Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

For more information on IPC The Hospitalist Company Inc. click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

TheStreet Quant Ratings

TRY IT FREE

New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:

Buy, hold, or sell recommendations for over 4,300 stocks
Unlimited research reports on your favorite stocks
A custom stock screener
Upgrade/downgrade alerts

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.